KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

JOURNAL ARTICLE published July 2013 in European Journal of Cancer

Authors: John C. Smith | Laura Brooks | Paulo M. Hoff | Gael McWalter | Simon Dearden | Shethah R. Morgan | David Wilson | Jane D. Robertson | Juliane M. Jürgensmeier